Treatment with the orally bioavailable BRD4 inhibitor MK-8628 suppresses medulloblastoma cell proliferation and induces apoptosis by reducing MYC expression, and MK-8628 suppresses medulloblastoma tumor progression in preclinical models [48]. The gene discussed is BRD4; the disease is neoplasm.